A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Sponsor: Cantex Pharmaceuticals
Terminated
Study stopped due to lack of efficacy.
Other terminated trials from Cantex Pharmaceuticals
More terminations from Cantex Pharmaceuticals
Listed as NCT02963051, this PHASE1 trial focuses on Prostate Cancer and remains terminated or withdrawn. Sponsored by Cantex Pharmaceuticals, it has been updated 12 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE1
-
Oct 2021 — Jul 2024 [monthly]
Terminated PHASE1
-
Jan 2021 — Oct 2021 [monthly]
Terminated PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Terminated PHASE1
Status: Active Not Recruiting → Terminated
▶ Show 7 earlier versions
-
Feb 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
-
Apr 2019 — Feb 2020 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
-
Jul 2018 — Apr 2019 [monthly]
Recruiting PHASE1
-
Jun 2018 — Jul 2018 [monthly]
Recruiting PHASE1
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
Feb 2017 — Aug 2017 [monthly]
Not Yet Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Cantex Pharmaceuticals
- Daniel George, MD
- Give 1 For Dad Campaign
- Peter Michael Foundation
- The V Foundation for Cancer Research
For direct contact, visit the study record on ClinicalTrials.gov .